Ignite Creation Date:
2024-05-06 @ 9:04 AM
Last Modification Date:
2024-10-26 @ 12:09 PM
Study NCT ID:
NCT02898116
Status:
COMPLETED
Last Update Posted:
2022-10-10
First Post:
2016-09-08
Brief Title:
Phase 12 Study of Ensartinib and Durvalumab in ALK-rearranged Non-small Cell Lung Cancer
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Ludwig Institute for Cancer Research
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-05-10
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-04
Completion Date Type:
ACTUAL
First Submit Date:
2016-09-08
First Submit QC Date:
September 12 2016
Study First Post Date:
2016-09-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2018-08-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-03
Last Update Post Date:
2022-10-10
Last Update Post Date Type:
ACTUAL